ABSTRACT

In a sector characterised by patenting, direct appropriations and returns from investment, the Structural Genomics Consortium (SGC) constitutes a radically different public-private and entirely open access approach to pre-competitive research. This paper discusses the significance of findings from the first independent review of the SGC. We argue that the SGC offers a shared knowledge resource for drug discovery which is distinctive from other types of knowledge production and, as such, provides a knowledge infrastructure for the wider scientific community. We distinguish three ways in which this infrastructure functions as a model for investing in, extracting value from, and generating knowledge for the field. Our analysis suggests there is a future for open science models such as the SGC in health research and innovation, but that such models raise a set of challenges over the role of different public and private institutional actors and the way in which value is extracted.

摘要

在以专利，直接拨款和投资回报为特征的行业中，结构基因组学联盟（SGC）构成了完全不同的公私合营的，完全开放的竞争前研究方法。本文讨论了SGC的第一次独立审核所得出的结论的意义。我们认为，SGC为药物发现提供了共享的知识资源，这与其他类型的知识生产截然不同，因此，它为更广泛的科学界提供了知识基础设施。我们区分了该基础架构作为模型进行投资，从中提取价值和为该领域生成知识的模型的三种方式。我们的分析表明，开放式科学模型（如​​SGC）在健康研究和创新，